Teva Acquires Ratiopharm - Analyst Blog

Teva Pharmaceutical Industries Ltd. (TEVA) recently announced the completion of its second major acquisition in a period of two years. The company announced that it has acquired Germany’s second largest generics producer, Ratiopharm, for an enterprise value of €3.625 billion plus accrued interest of €186 million (a total value of approximately $4.95 billion).

Teva’s last major acquisition was that of Barr Pharmaceuticals, a US-based multinational generic pharmaceutical company with operations mainly in the US and Europe. This acquisition boosted Teva’s product portfolio which now includes several generic pharmaceutical products as well as women’s health products.

Teva is no stranger to acquisitions. In addition to the Barr and Ratiopharm acquisitions, other major acquisitions in Teva’s history include those of Ivax Corp. (January 2006) and Sicor Inc. (January 2004).